It may directly, as well as other CXCR2 ligands, act on granulocyte and macrophage progenitor cells (GMPs), increasing the number of M-MDSCs in the bone marrow and thereby enhancing the recruitment intensity of these cells to the tumor niche by other factors [23]. The gene discussed is CXCR2; the disease is neoplasm.